Base de dados : MEDLINE
Pesquisa : D06.472.699.327.700.750 [Categoria DeCS]
Referências encontradas : 137 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 14 ir para página                         

  1 / 137 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16689317
[Au] Autor:Murai I; Oyama J; Kanazawa K
[Ad] Endereço:Department of Biochemistry, Nihon University School of Medicine.
[Ti] Título:[Prolactin: structure and regulation of pituitary secretion].
[So] Source:Nihon Rinsho;64 Suppl 4:251-7, 2006 Apr.
[Is] ISSN:0047-1852
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Mh] Termos MeSH primário: Adeno-Hipófise/secreção
Prolactina/química
Prolactina/secreção
[Mh] Termos MeSH secundário: Animais
Dopamina/fisiologia
Feminino
Hormônios Hipotalâmicos/fisiologia
Neuropeptídeos/fisiologia
Adeno-Hipófise/irrigação sanguínea
Veia Porta
Gravidez
Fatores Inibidores da Liberação da Prolactina/fisiologia
Hormônio Liberador de Prolactina
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hypothalamic Hormones); 0 (Neuropeptides); 0 (Prolactin-Releasing Hormone); 9002-62-4 (Prolactin); 9034-47-3 (Prolactin Release-Inhibiting Factors); VTD58H1Z2X (Dopamine)
[Em] Mês de entrada:0606
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:060513
[St] Status:MEDLINE


  2 / 137 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15049851
[Au] Autor:Bodnár I; Mravec B; Kubovcakova L; Tóth EB; Fülöp F; Fekete MI; Kvetnansky R; Nagy GM
[Ad] Endereço:Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovakia.
[Ti] Título:Stress- as well as suckling-induced prolactin release is blocked by a structural analogue of the putative hypophysiotrophic prolactin-releasing factor, salsolinol.
[So] Source:J Neuroendocrinol;16(3):208-13, 2004 Mar.
[Is] ISSN:0953-8194
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Prolactin is secreted from the anterior lobe of the pituitary gland in response both to suckling and to stress. We recently observed that 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol), produced in the neurointermediate lobe of the pituitary gland, as well as in the medial basal hypothalamus, can selectively release prolactin from the anterior pituitary. Therefore, it has been proposed that salsolinol is a putative endogenous prolactin-releasing factor (PRF). Here, we report that one structural analogue of salsolinol, 1-methyl-3,4-dihydroisoquinoline (1MeDIQ), can block salsolinol-induced release of prolactin, but does not affect prolactin release in response to thyrotropin releasing hormone (TRH), alpha-methyl-p-tyrosine (alpha MpT) (an inhibitor of tyrosine hydroxylase), domperidone (a D(2) dopamine receptor antagonist), or 5-hydroxytryptophan (5-HTP), a precursor of serotonin). 1MeDIQ profoundly inhibited suckling-, immobilization-, as well as formalin-stress induced prolactin release without any influence on corticosterone secretion. The 1MeDIQ-induced reduction in prolactin response to immobilization stress was dose-dependent. These results suggest that salsolinol can play a pivotal role in the regulation of prolactin release induced by either physiological (suckling) or environmental (stress) stimuli.
[Mh] Termos MeSH primário: Isoquinolinas/metabolismo
Isoquinolinas/farmacologia
Lactação/fisiologia
Adeno-Hipófise/efeitos dos fármacos
Prolactina/secreção
Estresse Psicológico/fisiopatologia
[Mh] Termos MeSH secundário: Adaptação Fisiológica
Animais
Animais Lactentes
Relação Dose-Resposta a Droga
Feminino
Isoquinolinas/química
Masculino
Adeno-Hipófise/secreção
Fatores Inibidores da Liberação da Prolactina/agonistas
Fatores Inibidores da Liberação da Prolactina/farmacologia
Ratos
Ratos Sprague-Dawley
Hormônio Liberador de Tireotropina/agonistas
Hormônio Liberador de Tireotropina/antagonistas & inibidores
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (1-methyl-3,4-dihydroisoquinoline); 0 (Isoquinolines); 5Y5F15120W (Thyrotropin-Releasing Hormone); 9002-62-4 (Prolactin); 9034-47-3 (Prolactin Release-Inhibiting Factors); 9ILS801M65 (salsolinol)
[Em] Mês de entrada:0406
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:040331
[St] Status:MEDLINE


  3 / 137 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9747213
[Au] Autor:Folchetti G; Morand JJ; Laurans R; Choux R; Hesse S
[Ad] Endereço:Service de Dermatologie, Hôpital Ste Marguerite, Marseille.
[Ti] Título:[Case for diagnosis. Neuro-sarcoidosis].
[Ti] Título:Cas pour diagnostic. Neuro-sarcoïdose].
[So] Source:Ann Dermatol Venereol;125(1):59-60, 1998 Jan.
[Is] ISSN:0151-9638
[Cp] País de publicação:France
[La] Idioma:fre
[Mh] Termos MeSH primário: Doenças da Hipófise/diagnóstico
Sarcoidose/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Diagnóstico Diferencial
Feminino
Seres Humanos
Hiperprolactinemia/etiologia
Doenças da Hipófise/complicações
Fatores Inibidores da Liberação da Prolactina/secreção
Sarcoidose/complicações
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
9034-47-3 (Prolactin Release-Inhibiting Factors)
[Em] Mês de entrada:9810
[Cu] Atualização por classe:061115
[Lr] Data última revisão:
061115
[Sb] Subgrupo de revista:IM; N
[Da] Data de entrada para processamento:980925
[St] Status:MEDLINE


  4 / 137 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:7760850
[Au] Autor:Wilson TM; Yu-Lee LY; Kelley MR
[Ad] Endereço:Department of Pediatrics, Wells Center for Pediatric Research, Indianapolis, Indiana, USA.
[Ti] Título:Coordinate gene expression of luteinizing hormone-releasing hormone (LHRH) and the LHRH-receptor after prolactin stimulation in the rat Nb2 T-cell line: implications for a role in immunomodulation and cell cycle gene expression.
[So] Source:Mol Endocrinol;9(1):44-53, 1995 Jan.
[Is] ISSN:0888-8809
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PRL has been shown to induce a number of genes after the stimulation of quiescent Nb2 T-cells, including c-fos, c-myc, ornithine decarboxylase, interferon regulatory factor-1, and others. One of these genes, LHRH, has not previously been reported to respond in this manner, although we and others have reported its presence in rat and human T- and B-cells. Furthermore, recent evidence suggests that LHRH functions as an immunoregulator in a cytokine-like manner. Using the rat immature T-cell line Nb2, we present data showing for the first time that 1) the LHRH gene is regulated by PRL at various times during the cell cycle; 2) an alternatively spliced LHRH messenger RNA exists in Nb2 cells and may produce a new truncated GnRH-associated peptide (alternatively called PIF for PRL-inhibiting factor); 3) the LHRH receptor is expressed in lymphocytes in a manner similar to the LHRH gene after PRL addition, and its complementary DNA sequence is identical to that of the pituitary receptor; 5) the SH gene, found on the opposite strand of the LHRH gene, is expressed in lymphocytes at the same time and in the same manner as the LHRH gene; 6) the LHRH messenger RNA has a very short half-life in these cells; and 7) the lymphocyte LHRH transcription start site is essentially the same as the hypothalamic site. These data strengthen the relationship between PRL and LHRH expression in the immune system and further support our contention that LHRH is an important immunoregulator, on par with other known cytokines.
[Mh] Termos MeSH primário: Regulação da Expressão Gênica
Hormônio Liberador de Gonadotropina/biossíntese
Fatores Inibidores da Liberação da Prolactina/biossíntese
Prolactina/farmacologia
Receptores LHRH/biossíntese
Linfócitos T/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Sequência de Bases
Ciclo Celular/genética
Regulação Neoplásica da Expressão Gênica
Hormônio Liberador de Gonadotropina/genética
Meia-Vida
Sistema Hipotálamo-Hipofisário/fisiologia
Linfoma de Células T
Modelos Genéticos
Dados de Sequência Molecular
Proteínas de Neoplasias/biossíntese
Proteínas de Neoplasias/genética
Neuroimunomodulação/genética
Fatores Inibidores da Liberação da Prolactina/genética
Processamento de RNA
RNA Antissenso/biossíntese
RNA Antissenso/genética
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
RNA Neoplásico/genética
RNA Neoplásico/metabolismo
Ratos
Receptores LHRH/genética
Linfócitos T/metabolismo
Transcrição Genética
Células Tumorais Cultivadas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Neoplasm Proteins); 0 (RNA, Antisense); 0 (RNA, Messenger); 0 (RNA, Neoplasm); 0 (Receptors, LHRH); 33515-09-2 (Gonadotropin-Releasing Hormone); 9002-62-4 (Prolactin); 9034-47-3 (Prolactin Release-Inhibiting Factors)
[Em] Mês de entrada:9506
[Cu] Atualização por classe:071114
[Lr] Data última revisão:
071114
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:950101
[St] Status:MEDLINE


  5 / 137 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1354354
[Au] Autor:Handwerger S; Harman I; Golander A; Handwerger DA
[Ad] Endereço:Department of Pediatrics, Duke University Medical Center, Durham, NC 27710.
[Ti] Título:Prolactin release from perifused human decidual explants; effects of decidual prolactin-releasing factor (PRL-RF) and prolactin release-inhibitory factor (PRL-IF).
[So] Source:Placenta;13(1):55-62, 1992 Jan-Feb.
[Is] ISSN:0143-4004
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The dynamics of prolactin release from human decidual explants were studied under basal conditions, in response to decidual prolactin-releasing factor (PRL-RF), and in response to PRL-RF in the presence of decidual prolactin release-inhibitory factor (PRL-IF) or other factors known to inhibit prolactin release in static cultures. Explants were perifused with medium at a rate of 6 ml/h, and the medium was collected at 5 min intervals. The explants released prolactin for up to 20 h without evidence of cell necrosis, with the rate of prolactin decreasing gradually from 3.9 +/- 0.1 ng/5 min during the first 2 h to 2.2 +/- 0.1 ng/5 min during the last 2 h of exposure. PRL-RF, a 23.5 KMr protein released by the placenta, stimulated a dose-dependent increase in prolactin release from the perifused explants that occurred within the first 5 min of exposure and persisted until the exposure to the releasing factor was discontinued. PRL-IF, a 35-45 K Mr protein released by the decidua, caused a dose-dependent inhibition of PRL-RF-mediated prolactin release. Dibutyryl cAMP, cholera toxin, sn-1, 2-dioctonylglycerol, PMA, and arachidonic acid, which inhibit basal prolactin release from static decidual cultures, also caused a dose-dependent inhibition of prolactin release in response to PRL-RF. In each instance, the maximal dose of the agents tested inhibited PRL-RF-mediated prolactin release by greater than 84 per cent. These results indicate that the stimulation of prolactin by PRL-RF is inhibited by PRL-IF and pharmacologic agents that inhibit basal prolactin release.(ABSTRACT TRUNCATED AT 250 WORDS)
[Mh] Termos MeSH primário: Decídua/metabolismo
Fatores Inibidores da Liberação da Prolactina/farmacologia
Prolactina/secreção
Hormônio Liberador de Tireotropina/farmacologia
[Mh] Termos MeSH secundário: Ácido Araquidônico/farmacologia
Células Cultivadas
Diglicerídeos/farmacologia
Relação Dose-Resposta Imunológica
Feminino
Seres Humanos
Proteína Quinase C/fisiologia
Radioimunoensaio
Acetato de Tetradecanoilforbol/farmacologia
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (1,2-diacylglycerol); 0 (Diglycerides); 26657-95-4 (dipalmitin); 27YG812J1I (Arachidonic Acid); 5Y5F15120W (Thyrotropin-Releasing Hormone); 9002-62-4 (Prolactin); 9034-47-3 (Prolactin Release-Inhibiting Factors); EC 2.7.11.13 (Protein Kinase C); NI40JAQ945 (Tetradecanoylphorbol Acetate)
[Em] Mês de entrada:9209
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:920101
[St] Status:MEDLINE


  6 / 137 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1677789
[Au] Autor:Bevers MM; Schaefers-Okkens AC
[Ti] Título:[Pseudopregnancy in the dog].
[Ti] Título:Schijnzwangerschap bij de hond..
[So] Source:Tijdschr Diergeneeskd;116(13):700, 1991 Jul 01.
[Is] ISSN:0040-7453
[Cp] País de publicação:Netherlands
[La] Idioma:dut
[Mh] Termos MeSH primário: Doenças do Cão/tratamento farmacológico
Fatores Inibidores da Liberação da Prolactina/uso terapêutico
Pseudogravidez/veterinária
[Mh] Termos MeSH secundário: Animais
Bromocriptina/uso terapêutico
Cães
Feminino
Metergolina/uso terapêutico
Gravidez
Pseudogravidez/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
1501393LY5 (Metergoline); 3A64E3G5ZO (Bromocriptine); 9034-47-3 (Prolactin Release-Inhibiting Factors)
[Em] Mês de entrada:9109
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:910701
[St] Status:MEDLINE


  7 / 137 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1980429
[Au] Autor:Shin SH; Hanna SF; Hong M; Jhamandas K
[Ad] Endereço:Department of Physiology, Queen's University, Kingston, Ont., Canada.
[Ti] Título:Reexamination of dopamine as the prolactin-release inhibiting factor (PIF): supplementary agent may be required for dopamine to function as the physiological PIF.
[So] Source:Can J Physiol Pharmacol;68(9):1226-30, 1990 Sep.
[Is] ISSN:0008-4212
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:A large number of studies have been performed concerning dopamine's inhibitory effect on prolactin release, but many of these studies have examined the effect of dopamine dissolved in a solution containing ascorbic acid. Ascorbic acid, routinely used to protect dopamine from oxidation, alone does not stimulate or inhibit prolactin release, but it can potentiate the inhibitory effect of dopamine in a static monolayer culture system by approximately 100 times. We have closely examined the inhibitory effect of dopamine on prolactin release in the absence of ascorbic acid using a perifusion system. Male rat adenohypophyses were dispersed with trypsin and cultured in a Petri dish to form cell clusters. Inhibition of prolactin release by dopamine (1 mumol/L) in the absence of ascorbic acid was sustained for only 63 min during the 2-h perifusion period. Following a 2-h period of incubation of dopamine in the same experimental solution, the dopamine concentration was reduced from 1 to 0.18 mumol/L, yet this "2-h-old dopamine" was still effective in inhibiting prolactin release (approximately 30 min). This result suggests that the lactotrophs may be desensitized by chronic exposure to a high concentration of dopamine in the absence of ascorbic acid. In contrast, when a low concentration of dopamine (3 nmol/L) containing ascorbic acid (0.1 mmol/L) was perifused, inhibition of prolactin release was sustained for the entire 2-h perifusion period. Although there may be a large number of explanations for dopamine's transient inhibitory effect on prolactin release, the present results suggest that dopamine may require supplementary agent(s) to effectively inhibit prolactin release and thus function as the prolactin release inhibitory factor (PIF).(ABSTRACT TRUNCATED AT 250 WORDS)
[Mh] Termos MeSH primário: Dopamina/farmacologia
Fatores Inibidores da Liberação da Prolactina/fisiologia
[Mh] Termos MeSH secundário: Animais
Ácido Ascórbico/farmacologia
Dopamina/fisiologia
Relação Dose-Resposta a Droga
Cinética
Masculino
Prolactina/metabolismo
Prolactina/secreção
Ratos
Ratos Endogâmicos
Somatostatina/farmacologia
Somatostatina/fisiologia
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
51110-01-1 (Somatostatin); 9002-62-4 (Prolactin); 9034-47-3 (Prolactin Release-Inhibiting Factors); PQ6CK8PD0R (Ascorbic Acid); VTD58H1Z2X (Dopamine)
[Em] Mês de entrada:9103
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:900901
[St] Status:MEDLINE


  8 / 137 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1972918
[Au] Autor:Shin SH; Stirling RG; Hanna S; Lim M; Wilson JX
[Ad] Endereço:Department of Physiology, Queen's University, Kingston, Ontario, Canada.
[Ti] Título:Ascorbic acid potentiates the inhibitory effect of dopamine on prolactin release: a putative supplementary agent for PIF.
[So] Source:Endocrinol Exp;24(1-2):151-8, 1990 Mar.
[Is] ISSN:0013-7200
[Cp] País de publicação:Slovakia
[La] Idioma:eng
[Ab] Resumo:Dopamine has a catechol group which can be easily oxidized by mild oxidizing agents. Ascorbic acid has been routinely added to a dopamine solution in order to protect it from oxidation. We have examined the effect of ascorbic acid on dopaminergic inhibition of prolactin release. Male rat pituitary cells were dispersed using trypsin and cultured for 5-7 days before experiments. Ascorbic acid did not stimulate nor inhibit prolactin release in both static monolayer culture and dynamic perifusion systems, but potentiated by approximately 100 times the inhibitory effect of dopamine on prolactin release. In order to differentiate chemical protection from potentiation, we tested the potentiation effect of isoascorbic acid which is an epimer of biologically active L-ascorbic acid but is biologically less active. Our results indicated that isoascorbic acid caused less potentiation of the dopaminergic effect on prolactin release than did ascorbic acid. In a perifusion system, a high concentration of dopamine (100 nmol/l) was unable to inhibit prolactin release for a 1 h experimental period, but a low concentration of dopamine (10 nmol/l) plus ascorbic acid (10 mumol/l) inhibited prolactin release for the entire 1 h perifusion period. There is a strong possibility that ascorbic acid may be a physiological supplementary agent for the prolactin-release inhibiting factor (PIF) since the blood concentration of ascorbic acid is rather high (23-85 mumol/l).
[Mh] Termos MeSH primário: Ácido Ascórbico/farmacologia
Dopamina/farmacologia
Fatores Inibidores da Liberação da Prolactina/fisiologia
Prolactina/metabolismo
[Mh] Termos MeSH secundário: Animais
Sinergismo Farmacológico
Masculino
Ratos
Ratos Endogâmicos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
9002-62-4 (Prolactin); 9034-47-3 (Prolactin Release-Inhibiting Factors); PQ6CK8PD0R (Ascorbic Acid); VTD58H1Z2X (Dopamine)
[Em] Mês de entrada:9008
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:900301
[St] Status:MEDLINE


  9 / 137 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:2572126
[Au] Autor:Shin SH; Obonsawin MC; Stirling R
[Ad] Endereço:Department of Physiology, Queen's University, Kingston, Ontario, Canada.
[Ti] Título:Bovine neurophysin-II stimulates prolactin release without involvement of dopaminergic prolactin-release inhibiting factor receptor in the estradiol-primed male rat.
[So] Source:Acta Endocrinol (Copenh);121(3):411-6, 1989 Sep.
[Is] ISSN:0001-5598
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:Neurophysins have been considered to be physiologically inert carrier proteins for the neurohypophysial hormones, oxytocin and vasopressin. We have observed that bovine neurophysin-II indirectly stimulates prolactin release in estradiol-primed male rats. The release of prolactin is regulated by a dual hypothalamic control system, the prolactin-release-inhibiting factor and the prolactin-releasing factor. We have tried to clarify whether neurophysin-II is acting through stimulation of prolactin-releasing factor by eliminating the possibility of dopaminergic prolactin release-inhibiting factor release. Male rats were primed with estradiol and functional dopaminergic prolactin release-inhibiting factor receptors were completely blocked by pretreatment with a large dose of pimozide (3 mg/kg), a dopaminergic receptor blocking agent. The neurophysin-II stimulated prolactin release in the rats which did not have any functional dopaminergic prolactin release-inhibiting factor receptors suggesting that neurophysin-II likely initiates a chain of events which eventually stimulates prolactin-releasing factor release since the possibility of involvement of the dopaminergic prolactin release-inhibiting factor system is eliminated. Opioids are known to be one of a chain of events which transmit external stress into a stimulation of prolactin release. Naloxone, a mu-receptor antagonist, was injected 20 min before neurophysin-II administration into rats which were primed with estradiol and pretreated with pimozide (3 mg/kg), but the naloxone administration did not block the prolactin release stimulated by neurophysin-II injection. This result indicates that opioids are not one of the chain of events between initiation of stimulation by neurophysin-II and prolactin release.
[Mh] Termos MeSH primário: Estradiol/administração & dosagem
Neurofisinas/administração & dosagem
Prolactina/secreção
Receptores Dopaminérgicos/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Masculino
Naloxona/administração & dosagem
Pimozida/administração & dosagem
Fatores Inibidores da Liberação da Prolactina/metabolismo
Ratos
Ratos Endogâmicos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Neurophysins); 0 (Receptors, Dopamine); 1HIZ4DL86F (Pimozide); 36B82AMQ7N (Naloxone); 4TI98Z838E (Estradiol); 9002-62-4 (Prolactin); 9034-47-3 (Prolactin Release-Inhibiting Factors)
[Em] Mês de entrada:8911
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:890901
[St] Status:MEDLINE


  10 / 137 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:2569847
[Au] Autor:Matrozov P; Stoeva I
[Ti] Título:[The regulation of prolactin secretion].
[Ti] Título:Regulatsiia na prolaktinovata sekretsiia..
[So] Source:Akush Ginekol (Sofiia);28(2):66-70, 1989.
[Is] ISSN:0324-0959
[Cp] País de publicação:Bulgaria
[La] Idioma:bul
[Mh] Termos MeSH primário: Prolactina/secreção
[Mh] Termos MeSH secundário: Animais
Dopamina/fisiologia
Feminino
Hormônios Esteroides Gonadais/fisiologia
Seres Humanos
Hipotálamo/fisiologia
Periodicidade
Fatores Inibidores da Liberação da Prolactina/fisiologia
Hormônio Liberador de Tireotropina/fisiologia
Peptídeo Intestinal Vasoativo/fisiologia
Ácido gama-Aminobutírico/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Gonadal Steroid Hormones); 37221-79-7 (Vasoactive Intestinal Peptide); 56-12-2 (gamma-Aminobutyric Acid); 5Y5F15120W (Thyrotropin-Releasing Hormone); 9002-62-4 (Prolactin); 9034-47-3 (Prolactin Release-Inhibiting Factors); VTD58H1Z2X (Dopamine)
[Em] Mês de entrada:8909
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:890101
[St] Status:MEDLINE



página 1 de 14 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde